# Chidamide for Refractory/Relapsed Peripheral T Cell Lymphoma

> **NCT02944812** · PHASE2 · UNKNOWN · sponsor: **Guangdong Provincial People's Hospital** · enrollment: 12 (estimated)

## Conditions studied

- Peripheral T Cell Lymphoma

## Interventions

- **DRUG:** Chidamide

## Key facts

- **NCT ID:** NCT02944812
- **Lead sponsor:** Guangdong Provincial People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-03
- **Primary completion:** 2019-01
- **Final completion:** 2019-01
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2016-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02944812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02944812, "Chidamide for Refractory/Relapsed Peripheral T Cell Lymphoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02944812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*